Helmholtz Gemeinschaft


Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[img] Other (Supplemental Material)

Item Type:Article
Title:Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis
Creators Name:Brune, S. and Høgestøl, E.A. and de Rodez Benavent, S.A. and Berg-Hansen, P. and Beyer, M.K. and Leikfoss, I.S. and Bos, S.D. and Sowa, P. and Brunborg, C. and Andorra, M. and Pulido Valdeolivas, I. and Asseyer, S. and Brandt, A. and Chien, C. and Scheel, M. and Blennow, K. and Zetterberg, H. and Kerlero de Rosbo, N. and Paul, F. and Uccelli, A. and Villoslada, P. and Berge, T. and Harbo, H.F.
Abstract:BACKGROUND: Serum neurofilament light (sNfL) chain is a promising biomarker reflecting neuro-axonal injury in multiple sclerosis (MS). However, the ability of sNfL to predict outcomes in real-world MS cohorts requires further validation. OBECTIVE: The aim of the study is to investigate the associations of sNfL concentration, magnetic resonance imaging (MRI) and retinal optical coherence tomography (OCT) markers with disease worsening in a longitudinal European multicentre MS cohort. METHODS: MS patients (n = 309) were prospectively enrolled at four centres and re-examined after 2 years (n = 226). NfL concentration was measured by single molecule array assay in serum. The patients' phenotypes were thoroughly characterized with clinical examination, retinal OCT and MRI brain scans. The primary outcome was disease worsening at median 2-year follow-up. RESULTS: Patients with high sNfL concentrations (⩾8 pg/mL) at baseline had increased risk of disease worsening at median 2-year follow-up (odds ratio (95% confidence interval) = 2.8 (1.5-5.3), p = 0.001). We found no significant associations of MRI or OCT measures at baseline with risk of disease worsening. CONCLUSION: Serum NfL concentration was the only factor associated with disease worsening, indicating that sNfL is a useful biomarker in MS that might be relevant in a clinical setting.
Keywords:Multiple Sclerosis, Biomarker, Serum Neurofilament Light Chain, Magnetic Resonance Imaging, Optical Coherence Tomography, Prognosis
Source:Multiple Sclerosis Journal
Publisher:Sage Publications
Page Range:1859-1870
Date:October 2022
Official Publication:https://doi.org/10.1177/13524585221097296
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library